Josh Armenia on Impact of Mutated Gene Analysis in Prostate Cancer

Josh Armenia, PhD
Published: Tuesday, Feb 21, 2017



Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the impact of a gene mutation analysis study in prostate cancer.

This study was a mutational significance analysis, conducted to detect novel genes and pathways in 918 patients with prostate cancer. Twenty-three novel genes were identified as a result.

Due to the large cohort, defining biomarkers in advanced disease are possible, says Armenia.

By comparing the genomic alternation across Gleason scores, markers of risk progression of advanced disease within primary tumors should also be a realistic opportunity.
SELECTED
LANGUAGE


Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the impact of a gene mutation analysis study in prostate cancer.

This study was a mutational significance analysis, conducted to detect novel genes and pathways in 918 patients with prostate cancer. Twenty-three novel genes were identified as a result.

Due to the large cohort, defining biomarkers in advanced disease are possible, says Armenia.

By comparing the genomic alternation across Gleason scores, markers of risk progression of advanced disease within primary tumors should also be a realistic opportunity.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x